PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

Retatrutide (LY3437943)

Retatrutide (developmental code **LY3437943**) is an investigational, 39-amino-acid synthetic peptide. By targeting the GLP-1, GIP, and glucagon receptors, it is studied for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD).

1. Chemical Structure and Biochemistry

Retatrutide is built on a modified GIP peptide backbone incorporating non-canonical amino acids and a long-chain fatty acid moiety.

  • Structural Modifications: Contains $\alpha$-aminoisobutyric acid (Aib) substitutions to prevent rapid cleavage by dipeptidyl peptidase-4 (DPP-4), alongside an $\alpha$-methyl-leucine ($\alpha$-MeLeu) residue to fine-tune receptor selectivity.
  • Albumin Binding: A C20 fatty diacid chain conjugated via a linker to a lysine side chain allows tight, reversible binding to plasma albumin, extending its elimination half-life to approximately 6 days for once-weekly dosing.

2. Mechanism of Action

Retatrutide acts as a balanced triple agonist across three distinct metabolic G-protein-coupled receptors:

  • GLP-1 Receptor (GLP-1R): Enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on hypothalamic satiety centers to suppress appetite.
  • GIP Receptor (GIPR): Augments postprandial insulin sensitivity and complements GLP-1-mediated reductions in caloric intake.
  • Glucagon Receptor (GCGR): Unlike dual agonists (such as Tirzepatide), glucagon receptor activation increases resting energy expenditure, stimulates hepatic lipid oxidation, and accelerates liver fat clearance.

3. Research and Applications

Developed by Eli Lilly, Retatrutide has demonstrated some of the largest weight-loss percentages recorded in pharmacological obesity trials.

  • Obesity & Weight Management: Phase 2 clinical trial data reported mean body weight reductions exceeding 24% at 48 weeks in the highest-dose cohorts, advancing the compound into Phase 3 (TRIUMPH) trials.
  • Hepatic Steatosis (MASLD/MASH): Investigated for its potent reduction of intrahepatic liver fat driven by direct glucagon receptor signaling.

Note: Retatrutide is an investigational compound undergoing Phase 3 clinical evaluation and is not yet FDA-approved for commercial clinical use.

Tags: Retatrutide LY3437943 triple-agonist GLP-1R GIPR GCGR glucagon-receptor-agonist incretin-mimetic obesity-research MASLD metabolic-peptide